Abstract
Bevacizumab (BVZ) is a humanized monoclonal antibody that has demonstrated benefit in the front-line, recurrent platinum-sensitive and recurrent platinum-resistant ovarian cancer settings. Phase III trials of BVZ in ovarian cancer show a benefit in the dose-intensity range of 2.5 mg/kg/week to 5 mg/kg/week, but the optimal dose of this drug is still unknown. Some evidence suggests that high-dose BVZ is associated with a higher incidence of adverse events. In addition, in many countries, health services have restricted access to BVZ due its high cost.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
